JAK1 and COVID-19: Patients from rural counties were more likely to receive EUA COVID-19-specific or repurposed drugs, including remdesivir (61% vs 56%), dexamethasone (62% vs 59%), and JAK1/2 inhibitors/IL-6 inhibitors (17% vs 15%) as illustrated in Supplementary Figures 2 and 3 for the main and sensitivity analyses, respectively.